CAPRISA

International Decade of Sciences for Sustainable Development Forum opens in Beijing

Retrieved on: 
星期日, 四月 28, 2024
Online, Education, United Nations, UNAM, AIDS, Research, Sustainable development, Science policy, Policy, Culture, TWAS, Non-governmental organization, Private sector, Vaccination, Research fellow, Information technology, Republic, Club, United Nations General Assembly, UN, Infection, Artificial intelligence, Engineering, Multimedia, Natural science, Division, Big data, CAPRISA, UNGA, CRI, HIV/AIDS, Environment, Sustainable Development Goals, Ministry, UNESCO, Quarantine, COVID-19, Management

BEIJING, April 28, 2024 /PRNewswire/ -- A news report from CRI Online:

Key Points: 
  • BEIJING, April 28, 2024 /PRNewswire/ -- A news report from CRI Online:
    In August 2023, the United Nations General Assembly (UNGA) adopted the resolution "International Decade of Sciences for Sustainable Development 2024-2033" (Sciences Decade).
  • UNESCO, in collaboration with the Ministry of Science and Technology of the People's Republic of China and the People's Government of Beijing Municipality, co-organized the "International Decade of Sciences for Sustainable Development Forum" on April 25, Beijing, China.
  • The primary objective of the International Decade of Sciences for Sustainable Development Forum is to foster a culture of science by expanding the outreach of the Science Decade, engaging with the scientific community, government entities, the private sector, and civil societies on the vision and mission of the Decade, and mobilizing various stakeholders for its effective implementation.
  • The Science Decade echoes the annual theme of the 2024 ZGC Forum, "Innovation: Building a Better World", and further demonstrates the internationalization of the ZGC Forum.

Biktarvy® Demonstrates High Rates of Viral Suppression in People With HIV and Comorbidities

Retrieved on: 
星期三, 三月 6, 2024
Biotechnology, AIDS, Hospitals, Health, Pharmaceutical, ARV, Week, Research, Doctor of Philosophy, CROI, Science, CAPRISA, TLD, Fever, Coinfection, TB, STR, Common, Health care, Organization, DTG, Drug resistance, Genotype, HBV, Fungal infection, Principal, Rifampicin, Seroconversion, Tablet, ALT, TDF, Conference, Safety, Biomarker, Pharmacokinetics, Integrase, Metabolism, Emtricitabine, Aes, Gilead Sciences, MD, FDA, Upper respiratory tract infection, Food, Cell, Risk, Prevalence, COVID-19, Death, Patient, HIV/AIDS, Tuberculosis, INSIGHT, HIV, Vaccine

“People with HIV and comorbid conditions or pre-existing treatment resistance can often face complex and evolving treatment needs.

Key Points: 
  • “People with HIV and comorbid conditions or pre-existing treatment resistance can often face complex and evolving treatment needs.
  • The ALLIANCE trial is the first randomized clinical trial of TAF- vs TDF-based regimens in treatment naïve adults with HIV /HBV coinfection.
  • Additionally, ALLIANCE participants treated with Biktarvy exhibited numerically higher levels of HBV viral suppression and seroconversion.
  • The primary outcome measure is viral suppression rates at Week 24, defined as HIV-1 RNA ˂50 copies/mL.

CAPRISA and Evotec Launch New Project to Fast-Track New Technology for HIV Prevention

Retrieved on: 
星期一, 十月 25, 2021
Biotechnology, AIDS, Health, Pharmaceutical, Clinical Trials, Woman, Science, Statistics, Neurology, Research, Biotechnology, AIDS, University, Virology, LinkedIn, Vaccine Research Center, CAPRISA, HIV/AIDS, University of the Western Cape, Ethics, NIH, Human, European Union, Twitter, Patient, Infection, Republic, Machine learning, Molecular epidemiology, Health policy, University of KwaZulu-Natal, Clinical trial, Antibody, VRC, Center, Nelson, National Institute for Communicable Diseases, Evotec, Man, Union, Artificial intelligence, National Institute, Just, Kniphofia, Columbia University, WHO, Therapy, National Institute of Allergy and Infectious Diseases, Center for Infectious Disease Research and Policy, Medical specialty, University of Cape Town, HIV, Vaccine, Pharmaceutical industry, Fine chemical, Evotec, CAPRISA, EVOTEC, CAPRISA

The principal aim of the new joint project is to change the course of the HIV epidemic in Africa, which has 70% of the global HIV burden.

Key Points: 
  • The principal aim of the new joint project is to change the course of the HIV epidemic in Africa, which has 70% of the global HIV burden.
  • The next step is to assess if the antibody can prevent HIV infection in humans as effectively as it does in monkeys.
  • If shown to be effective in preventing HIV, the antibody, in conjunction with the VRCs VRC07 antibody, has the potential to break the HIV infection cycle.
  • Prof Salim Abdool Karim, Director of CAPRISA: We are excited to work with Evotec and the VRC in this project to improve the CAP256 manufacturing processes.